The Fort Worth Press - Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026

USD -
AED 3.672504
AFN 64.000368
ALL 80.878301
AMD 368.276037
ANG 1.789884
AOA 918.000367
ARS 1398.655759
AUD 1.37836
AWG 1.8025
AZN 1.70397
BAM 1.65809
BBD 2.008732
BDT 122.377178
BGN 1.668102
BHD 0.376584
BIF 2968.504938
BMD 1
BND 1.264635
BOB 6.891611
BRL 4.915095
BSD 0.997329
BTN 94.180832
BWP 13.389852
BYN 2.818448
BYR 19600
BZD 2.00585
CAD 1.36715
CDF 2265.000362
CHF 0.776955
CLF 0.022646
CLP 890.873638
CNY 6.80075
CNH 6.796265
COP 3727.014539
CRC 458.479929
CUC 1
CUP 26.5
CVE 93.480565
CZK 20.636704
DJF 177.601628
DKK 6.340404
DOP 59.310754
DZD 132.326735
EGP 52.744691
ERN 15
ETB 155.726591
EUR 0.84804
FJD 2.18304
FKP 0.733957
GBP 0.73346
GEL 2.67504
GGP 0.733957
GHS 11.234793
GIP 0.733957
GMD 73.503851
GNF 8750.794795
GTQ 7.614768
GYD 208.672799
HKD 7.83165
HNL 26.513501
HRK 6.393304
HTG 130.575219
HUF 300.190388
IDR 17377.45
ILS 2.901304
IMP 0.733957
INR 94.425504
IQD 1306.515196
IRR 1311500.000352
ISK 122.010386
JEP 0.733957
JMD 157.187063
JOD 0.70904
JPY 156.678504
KES 128.803357
KGS 87.420504
KHR 4001.526006
KMF 418.00035
KPW 899.983822
KRW 1461.920383
KWD 0.30766
KYD 0.831164
KZT 460.946971
LAK 21871.900301
LBP 89311.771438
LKR 321.097029
LRD 183.01047
LSL 16.361918
LTL 2.95274
LVL 0.60489
LYD 6.306642
MAD 9.121445
MDL 17.054809
MGA 4165.995507
MKD 52.257217
MMK 2099.83295
MNT 3581.379784
MOP 8.041456
MRU 39.863507
MUR 46.820378
MVR 15.403739
MWK 1729.049214
MXN 17.177604
MYR 3.921039
MZN 63.910377
NAD 16.361918
NGN 1365.000344
NIO 36.700437
NOK 9.209304
NPR 150.68967
NZD 1.675884
OMR 0.384681
PAB 0.997329
PEN 3.448264
PGK 4.404222
PHP 60.515038
PKR 277.958713
PLN 3.59545
PYG 6092.153787
QAR 3.645458
RON 4.426304
RSD 99.504048
RUB 74.240007
RWF 1462.082998
SAR 3.767486
SBD 8.019432
SCR 14.874401
SDG 600.503676
SEK 9.215704
SGD 1.267404
SHP 0.746601
SLE 24.650371
SLL 20969.496166
SOS 569.963122
SRD 37.399038
STD 20697.981008
STN 20.770633
SVC 8.727057
SYP 110.56358
SZL 16.351151
THB 32.203038
TJS 9.305159
TMT 3.5
TND 2.896867
TOP 2.40776
TRY 45.347504
TTD 6.759357
TWD 31.316038
TZS 2598.109449
UAH 43.809334
UGX 3737.018354
UYU 39.777881
UZS 12097.83392
VES 499.23597
VND 26308
VUV 118.45862
WST 2.707065
XAF 556.107838
XAG 0.012445
XAU 0.000212
XCD 2.70255
XCG 1.797465
XDR 0.69162
XOF 556.107838
XPF 101.106354
YER 238.625037
ZAR 16.38071
ZMK 9001.203584
ZMW 18.98775
ZWL 321.999592
  • JRI

    0.0000

    13.15

    0%

  • BCC

    -2.0900

    70.67

    -2.96%

  • RIO

    2.2700

    105.38

    +2.15%

  • BCE

    -0.4300

    24.14

    -1.78%

  • RBGPF

    0.7000

    63.61

    +1.1%

  • RELX

    0.0759

    33.58

    +0.23%

  • CMSD

    0.1140

    23.534

    +0.48%

  • CMSC

    0.1400

    23.11

    +0.61%

  • RYCEF

    -0.4100

    16.37

    -2.5%

  • NGG

    0.9800

    86.89

    +1.13%

  • BTI

    0.2000

    58.28

    +0.34%

  • GSK

    -0.0900

    50.41

    -0.18%

  • AZN

    0.3300

    182.85

    +0.18%

  • BP

    -0.4700

    43.34

    -1.08%

  • VOD

    0.5100

    16.2

    +3.15%

Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026
Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026

Todd H. Lanman to Present First Full U.S. IDE Trial Results for FDA-Approved Synergy Disc(R) at ISASS 2026

Beverly Hills spine surgeon and principal investigator will present pooled clinical outcomes following recent FDA approval of motion-preserving cervical disc technology

Text size:

BEVERLY HILLS, CA / ACCESS Newswire / April 2, 2026 / Following the recent FDA Premarket Approval (PMA) of the Synergy Disc®, Todd H. Lanman, MD, a pioneer in motion-preserving spine surgery, will present the first full results from the U.S. Investigational Device Exemption (IDE) clinical trial at the International Society for the Advancement of Spine Surgery (ISASS) 2026 Annual Conference in Miami Beach, April 9-11. Dr. Lanman served as a principal investigator in the multicenter U.S. IDE study evaluating the motion-preserving cervical artificial disc, developed by Synergy Spine Solutions, for the treatment of single-level degenerative disc disease from C3-C7.

The Synergy Disc received FDA approval after demonstrating superiority to anterior cervical discectomy and fusion (ACDF) on the study's primary endpoint of composite clinical success at 24 months. In the IDE trial, the device achieved an 87.1% composite clinical success rate, significantly higher than the fusion control group.

Additional key findings included:

91.7% of patients achieved clinically meaningful improvement on the Neck Disability Index at two years compared with 75.2% in the fusion group

Lower mean neck pain scores in the Synergy Disc group (15.6 vs. 30.2 in the fusion cohort)

Lower worst arm pain scores (15.0 vs. 32.2)

Improved segmental alignment, with disc angle increasing from 2.6 degrees pre-operatively to 6.5 degrees at 24 months

Higher patient satisfaction, reported by 84.5% of Synergy Disc patients versus 61.6% of fusion patients

"Artificial disc replacement continues to evolve rapidly, and these IDE results tell a clear story - meaningful reductions in neck and arm pain, better function, and higher patient satisfaction over fusion," said Dr. Lanman. "For patients, that is just not a statistic. That is the ability to return to an active, unrestricted life. That is what motion preservation is ultimately about."

The Synergy device incorporates a lordotic polyethylene core engineered to preserve motion while improving spinal alignment, a design intended to reduce the risk of postoperative kyphosis and maintain physiologic cervical curvature.

Dr. Lanman's presentation at ISASS will provide spine surgeons with a detailed review of the IDE trial methodology, clinical outcomes, and implications for the future of cervical motion-preserving surgery.

The International Society for the Advancement of Spine Surgery (ISASS) Annual Conference is one of the premier scientific meetings dedicated to spine innovation and motion-preservation technologies. The 2026 meeting will bring together leading spine surgeons, researchers, and industry innovators to discuss emerging technologies and advances in spinal care.

About Dr. Todd H. Lanman

Todd Lanman, MD has over three decades of experience as a spinal neurosurgeon and has spent the last 25 years practicing spine surgery in Beverly Hills. In addition to being a world-renowned spinal surgeon, Dr. Lanman has also had 11 spinal surgeries including spinal fusions and artificial disc replacements. Because of these experiences as surgeon and as patient, Dr. Lanman brings a unique perspective to his surgical practice.

About Lanman Spinal Neurosurgery

Lanman Spinal Neurosurgery is committed to improving patients' quality of life by relieving pain and restoring spinal motion. The Beverly Hills practice has been at the leading edge of spine health for the past quarter of a century. Lanman Spinal Neurosurgery has and continues to pioneer artificial disc replacement and fusion revision surgeries to help neck and back pain sufferers live their best lives.

About Synergy Spine Solutions

Synergy Spine Solutions is a medical device company focused on improving the quality of life for patients undergoing spine surgery. The company develops motion-preserving technologies designed to treat degenerative disc disease while supporting the spine's natural curvature. Its flagship product, the FDA-approved Synergy Disc®, features a built-in 6-degree lordotic core designed to not only preserve motion but also improve sagittal alignment.

Media Contact:

Brandi Kamenar
Brandi Kamenar Brand Management
BrandiKamenar.com
Email: [email protected]
Phone: (310) 734-6180

SOURCE: Lanman Spinal Neurosurgery



View the original press release on ACCESS Newswire

P.Grant--TFWP